CANY
KURA icon

Caxton Associates (New York)’s Kura Oncology KURA Stock Holding History

Caxton Associates (New York)’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,194
Closed -$244K – 653
2022
Q1 		$244K Sell
15,194
-11,841
-44% -$171K 0.02% 399
2021
Q4 		$378K Buy
+27,035
New +$438K 0.04% 346

Other funds holding KURA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Caxton Associates (New York)'s KURA Position: Q2 2022 in Review

Caxton Associates (New York) sold out of Kura Oncology (KURA) in Q2 2022, closing a stake of 15,194 shares — an estimated $244K sold.

Caxton Associates (New York) first reported a position in KURA in Q4 2021 and held it in 2 quarters. The position peaked at $378K in Q4 2021. 148 funds tracked by Wall St. Rank hold KURA as of Q2 2022.

  • Caxton Associates (New York) reported no remaining Kura Oncology position as of Q2 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 15,194 Kura Oncology shares in Q2 2022, an estimated $244K.
  • Caxton Associates (New York) first reported a position in Kura Oncology in Q4 2021 and held it in 2 quarters.
  • Caxton Associates (New York)'s Kura Oncology position peaked at $378K in Q4 2021.
  • 148 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2022.

Based on Caxton Associates (New York)'s 13F filing for Q2 2022, filed 15 Aug 2022.